Sugi Predict
/ Targets
/ UBA3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to UBA3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients |
PHASE4 | NOT_YET_RECRUITING |
| To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults |
PHASE3 | WITHDRAWN |
| Olaparib in Patients With HRD Malignant Mesothelioma |
PHASE2 | RECRUITING |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma |
PHASE2 | SUSPENDED |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma |
PHASE2 | WITHDRAWN |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection |
PHASE2 | WITHDRAWN |
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers |
PHASE2 | NOT_YET_RECRUITING |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes |
PHASE2 | UNKNOWN |
| MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma |
PHASE2 | WITHDRAWN |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) |
PHASE1 | COMPLETED |
| PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck |
PHASE1 | COMPLETED |
| Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis |
nan | UNKNOWN |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 |
nan | RECRUITING |
| Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome |
nan | RECRUITING |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome |
nan | RECRUITING |
| Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors |
nan | NOT_YET_RECRUITING |
| The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin |
nan | UNKNOWN |
| HRQoL and Financial Toxicity in Patients With VEXAS Syndrome |
nan | RECRUITING |
| Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
| A Natural History Study of Angelman Syndrome |
nan | RECRUITING |
| Inhibition of SENP1 for the Suppression of OS Growth and Metastasis |
nan | UNKNOWN |
| Establishment of a Prospective Clinical-biological Database |
nan | RECRUITING |
| Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) |
nan | UNKNOWN |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders |
nan | RECRUITING |
| Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 |
nan | NOT_YET_RECRUITING |
| Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men |
nan | RECRUITING |
| Investigation of Copy Number Variations and Genetic Variants in POI |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a UBA3 binder may also engage these)